Clinical Pharmacology-Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy
JournalClinical and Translational Science
PublisherBlackwell Publishing Ltd
MetadataShow full item record
AbstractOral sotalol, used in adults for sinus rhythm control, is initiated at 80 mg b.i.d. and titrated to a maximum safe dose. The US Food and Drug Administration recommends monitoring the corrected QT interval (QTc) for at least 3 days, until steady-state exposure of the drug is reached, before patient discharge, which can significantly impact the total cost of treatment. The objectives of this research were to design an accelerated intravenous sotalol loading and maintenance therapy that will reduce the hospital length of stay and to also evaluate the pharmacoeconomic impact in a hospital setting. Pharmacokinetic simulations of sotalol plasma concentrations vs. times profiles were performed to determine the optimal intravenous/oral transition regimen. A cost minimization analysis from the health sector perspective was conducted to assess the cost savings for these proposed accelerated regimens. For a chosen target dose of 120 mg b.i.d., two infusions of 40 mg over 1 hour and 20 mg over 0.5 hour, each followed up by an evaluation of QTc, can be administered followed immediately by the target oral maintenance dose of 120 mg at the end of the second infusion. Consequently, steady-state exposure and, therefore, steady-state QTc are obtained on the first day of therapy, facilitating an earlier hospital discharge. Two and 1-day mean total cost of −$3,123 (95% confidence interval (CI), −$3,640, −$2,607) −$4,820 (95% CI, −$5,352, −$4,288) were observed for this strategy, respectively. We are proposing an intravenous to oral transition strategy for sotalol that has the potential to significantly reduce cost and increase patient convenience. Copyright 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85070688948&doi=10.1111%2fcts.12670&partnerID=40&md5=4ee290d79b90ebf7f5682a3e075c62dd; http://hdl.handle.net/10713/10396
- Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
- Authors: Barbey JT, Sale ME, Woosley RL, Shi J, Melikian AP, Hinderling PH
- Issue date: 1999 Jul
- Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
- Authors: Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A
- Issue date: 2008 Jun
- Developing a safe intravenous sotalol dosing regimen.
- Authors: Somberg JC, Preston RA, Ranade V, Molnar J
- Issue date: 2010 Jul-Aug
- Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
- Authors: Kim RJ, Juriansz GJ, Jones DR, Gerling BR, Holzberger PT, Greenberg ML
- Issue date: 2006 Nov
- Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers.
- Authors: Uematsu T, Kanamaru M, Nakashima M
- Issue date: 1994 Jul